Bone Metastases: An Overview
暂无分享,去创建一个
Nuno Bonito | F. Macedo | K. Ladeira | Filipa Pinho | Nadine Saraiva | N. Bonito | L. Pinto | Francisco Gonçalves | Filipa Macedo | Katia Ladeira | Filipa Pinho | Nadine Saraiva | Luisa Pinto | Francisco Goncalves | Filipa Pinho
[1] K. Kelly,et al. Mechanisms of cancer metastasis to the bone , 2005, Cell Research.
[2] M. Okcu,et al. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. , 2004, Journal of pediatric surgery.
[3] E. B. Butler,et al. Stereotactic body radiotherapy in the management of painful bone metastases. , 2008, Oncology.
[4] M. Aapro,et al. Bone health in cancer patients: ESMO Clinical Practice Guidelines. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Hayman,et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. , 1990, Cancer research.
[6] J. Moore,et al. Bone Metastasis , 1982, British Journal of Cancer.
[7] M. Piccart,et al. Use of bisphosphonates in cancer patients. , 1996, Cancer treatment reviews.
[8] H. Goldschmidt,et al. Bisphosphonates in multiple myeloma. , 2001, The Cochrane database of systematic reviews.
[9] S. Kitazawa,et al. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases , 2005, Surgery Today.
[10] N. Janjan. Radiation for bone metastases , 1997, Cancer.
[11] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[13] R. Coleman,et al. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. , 2001, Seminars in oncology.
[14] R. Eastell,et al. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. , 1996, Cancer treatment reviews.
[15] O. S. Nielsen,et al. Bone metastases: pathophysiology and management policy. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[17] R. Marcove,et al. The management of pathological fractures. , 1965, The Journal of trauma.
[18] M. Gnant,et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] F. Balkwill. Cancer and the chemokine network , 2004, Nature Reviews Cancer.
[20] D. Haber,et al. A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases , 2013, Clinical Cancer Research.
[21] S. Gruber,et al. Use of bisphosphonates and reduced risk of colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] I. Mazo,et al. Adhesion and homing of blood‐borne cells in bone marrow microvessels , 1999, Journal of leukocyte biology.
[23] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[24] P. Rubin,et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. , 1992, International journal of radiation oncology, biology, physics.
[25] J. A. Spicer,et al. Clinical experience with strontium-89 in prostatic and breast cancer patients. , 1993, Seminars in oncology.
[26] R. Baron,et al. Denosumab and bisphosphonates: different mechanisms of action and effects. , 2011, Bone.
[27] D. Goulis,et al. Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[28] C. Chung,et al. The Role of Stereotactic Radiosurgery in Metastasis to the Spine , 2012, Journal of Korean Neurosurgical Society.
[29] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[30] J. Saliken,et al. CT for monitoring cryotherapy. , 1996, AJR. American journal of roentgenology.
[31] M. Robson,et al. How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/Oncology Clinics of North America.
[32] G. Naumov,et al. Critical steps in hematogenous metastasis: an overview. , 2001, Surgical oncology clinics of North America.
[33] G. Karsenty,et al. Transcription factors in bone: developmental and pathological aspects. , 2002, Trends in molecular medicine.
[34] D. Tong,et al. The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.
[35] D. Rosenthal. Radiologic diagnosis of bone metastases , 1997, Cancer.
[36] Cheng Huang,et al. Zoledronic Acid as an Adjuvant Therapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis , 2012, PloS one.
[37] H. Lilja,et al. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. , 1996, Urology.
[38] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[39] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[40] M. Mohiuddin,et al. Single‐dose half‐body irradiation for palliation of multiple bone metastases from solid tumors: Final radiation therapy oncology group report , 1986, Cancer.
[41] S. Cascinu,et al. Novel therapeutic approaches to cancer patients with bone metastasis. , 2001, Critical reviews in oncology/hematology.
[42] P. Novotny,et al. Percutaneous image‐guided cryoablation of painful metastases involving bone , 2013, Cancer.
[43] N. Raje,et al. Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients , 2012, Clinical interventions in aging.
[44] J A Kanis,et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. , 1994, Bone.
[45] K. Pienta,et al. Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone , 2004, Cancer and Metastasis Reviews.
[46] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[47] Antoinette Wetterwald,et al. Molecular and Biological Mechanisms of Bone Metastasis , 2005 .
[48] P. Mantyh,et al. Bone cancer pain , 2010, Annals of the New York Academy of Sciences.
[49] M. Rogers,et al. Overview of bisphosphonates , 1997, Cancer.
[50] L. M. Franks. The spread of prostatic carcinoma to the bones. , 1953, The Journal of pathology and bacteriology.
[51] Xiaojuan Xiong,et al. Inhibition of Growth of Dictyostelium discoideum Amoebae by Bisphosphonate Drugs Is Dependent on Cellular Uptake , 1997, Pharmaceutical Research.
[52] M. Rogers,et al. Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption , 2002 .
[53] J Kotzerke,et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] C. Gialeli,et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. , 2012, Biochimica et biophysica acta.
[55] G. Rennert,et al. Use of bisphosphonates and risk of postmenopausal breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] G. Scagliotti,et al. Management of bone metastases in cancer: a review. , 2005, Critical reviews in oncology/hematology.
[57] J. Mandrekar,et al. Palliation of painful metastatic disease involving bone with imaging-guided treatment: comparison of patients' immediate response to radiofrequency ablation and cryoablation. , 2011, AJR. American journal of roentgenology.
[58] E. Abt,et al. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review , 2011, Nature Reviews Endocrinology.
[59] Xunbin Wei,et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment , 2005, Nature.
[60] J. Manson,et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] F. Saad,et al. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid , 2012, Therapeutic advances in urology.
[62] K. Goa,et al. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. , 2003, Drugs.
[63] P C Goodman,et al. Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.
[64] R. Wahl,et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.
[65] A. Evans,et al. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. , 2000, Clinical radiology.
[66] R. Coleman. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.
[67] G. Scagliotti,et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] G. Steger,et al. Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion , 2011, Therapeutic advances in medical oncology.
[69] M. Tiemann,et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation , 2010, International journal of cancer.
[70] K. Luzzi,et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. , 1998, The American journal of pathology.
[71] G. Scagliotti,et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] R. Rubens,et al. The clinical course of bone metastases from breast cancer. , 1987, British Journal of Cancer.